Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice

Poongothai Venkatachalapathy,1 Sruthi Padhilahouse,1 Mohan Sellappan,1 Tharunika Subramanian,2 Shilia Jacob Kurian,3 Sonal Sekhar Miraj,3 Mahadev Rao,3 Ashwin Ashok Raut,4 Rupinder Kaur Kanwar,4 Jitendra Singh,4 Sagar Khadanga,5 Sukumar Mondithoka,5 Murali Munisamy4 1Department of Pharmacy Practice,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian SJ, Miraj SS, Rao M, Raut AA, Kanwar RK, Singh J, Khadanga S, Mondithoka S, Munisamy M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	pharmacogenomics personalized medicine type 2 diabetes antidiabetic drugs Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5053c2f23b274392ac1de3c5ab3daa10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5053c2f23b274392ac1de3c5ab3daa10
record_format	dspace
spelling	oai:doaj.org-article:5053c2f23b274392ac1de3c5ab3daa102021-11-14T19:00:30ZPharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice1178-7066https://doaj.org/article/5053c2f23b274392ac1de3c5ab3daa102021-11-01T00:00:00Zhttps://www.dovepress.com/pharmacogenomics-and-personalized-medicine-in-type-2-diabetes-mellitus-peer-reviewed-fulltext-article-PGPMhttps://doaj.org/toc/1178-7066Poongothai Venkatachalapathy,1 Sruthi Padhilahouse,1 Mohan Sellappan,1 Tharunika Subramanian,2 Shilia Jacob Kurian,3 Sonal Sekhar Miraj,3 Mahadev Rao,3 Ashwin Ashok Raut,4 Rupinder Kaur Kanwar,4 Jitendra Singh,4 Sagar Khadanga,5 Sukumar Mondithoka,5 Murali Munisamy4 1Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, Tamilnadu, India; 2Karpagam Faculty of Medical Sciences and Research, Coimbatore, India; 3Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India; 4Translational Medicine Centre, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India; 5Department of General Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, IndiaCorrespondence: Murali MunisamyTranslational Medicine Centre, All India Institute of Medical Sciences, Bhopal, 462020, Madhya Pradesh, India, Tel +91-9600-883-284Email murali.tmc@aiimsbhopal.edu.inAbstract: Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, and is rising in incidence with widespread prevalence. Multiple gene variants are associated with glucose homeostasis, complex T2DM pathogenesis, and its complications. Exploring more effective therapeutic strategies for patients with diabetes is crucial. Pharmacogenomics has made precision medicine possible by allowing for individualized drug therapy based on a patient’s genetic and genomic information. T2DM is treated with various classes of oral hypoglycemic agents, such as biguanides, sulfonylureas, thiazolidinediones, meglitinides, DPP4 inhibitors, SGLT2 inhibitors, α-glucosidase inhibitors, and GLP1 analogues, which exhibit various pharmacogenetic variants. Although genomic interventions in monogenic diabetes have been implemented in clinical practice, they are still in the early stages for complex polygenic disorders, such as T2DM. Precision DM medicine has the potential to be effective in personalized therapy for those suffering from various forms of DM, such as T2DM. With recent developments in genetic techniques, the application of candidate-gene studies, large-scale genotyping investigations, genome-wide association studies, and “multiomics” studies has begun to produce results that may lead to changes in clinical practice. Enhanced knowledge of the genetic architecture of T2DM presents a bigger translational potential. This review summarizes the genetics and pathophysiology of T2DM, candidate-gene approaches, genome-wide association studies, personalized medicine, clinical relevance of pharmacogenetic variants associated with oral hypoglycemic agents, and paths toward personalized diabetology.Keywords: pharmacogenomics, personalized medicine, type 2 diabetes, antidiabetic drugsVenkatachalapathy PPadhilahouse SSellappan MSubramanian TKurian SJMiraj SSRao MRaut AAKanwar RKSingh JKhadanga SMondithoka SMunisamy MDove Medical Pressarticlepharmacogenomicspersonalized medicinetype 2 diabetesantidiabetic drugsTherapeutics. PharmacologyRM1-950ENPharmacogenomics and Personalized Medicine, Vol Volume 14, Pp 1441-1455 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pharmacogenomics personalized medicine type 2 diabetes antidiabetic drugs Therapeutics. Pharmacology RM1-950
spellingShingle	pharmacogenomics personalized medicine type 2 diabetes antidiabetic drugs Therapeutics. Pharmacology RM1-950 Venkatachalapathy P Padhilahouse S Sellappan M Subramanian T Kurian SJ Miraj SS Rao M Raut AA Kanwar RK Singh J Khadanga S Mondithoka S Munisamy M Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
description	Poongothai Venkatachalapathy,1 Sruthi Padhilahouse,1 Mohan Sellappan,1 Tharunika Subramanian,2 Shilia Jacob Kurian,3 Sonal Sekhar Miraj,3 Mahadev Rao,3 Ashwin Ashok Raut,4 Rupinder Kaur Kanwar,4 Jitendra Singh,4 Sagar Khadanga,5 Sukumar Mondithoka,5 Murali Munisamy4 1Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, Tamilnadu, India; 2Karpagam Faculty of Medical Sciences and Research, Coimbatore, India; 3Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India; 4Translational Medicine Centre, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India; 5Department of General Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, IndiaCorrespondence: Murali MunisamyTranslational Medicine Centre, All India Institute of Medical Sciences, Bhopal, 462020, Madhya Pradesh, India, Tel +91-9600-883-284Email murali.tmc@aiimsbhopal.edu.inAbstract: Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, and is rising in incidence with widespread prevalence. Multiple gene variants are associated with glucose homeostasis, complex T2DM pathogenesis, and its complications. Exploring more effective therapeutic strategies for patients with diabetes is crucial. Pharmacogenomics has made precision medicine possible by allowing for individualized drug therapy based on a patient’s genetic and genomic information. T2DM is treated with various classes of oral hypoglycemic agents, such as biguanides, sulfonylureas, thiazolidinediones, meglitinides, DPP4 inhibitors, SGLT2 inhibitors, α-glucosidase inhibitors, and GLP1 analogues, which exhibit various pharmacogenetic variants. Although genomic interventions in monogenic diabetes have been implemented in clinical practice, they are still in the early stages for complex polygenic disorders, such as T2DM. Precision DM medicine has the potential to be effective in personalized therapy for those suffering from various forms of DM, such as T2DM. With recent developments in genetic techniques, the application of candidate-gene studies, large-scale genotyping investigations, genome-wide association studies, and “multiomics” studies has begun to produce results that may lead to changes in clinical practice. Enhanced knowledge of the genetic architecture of T2DM presents a bigger translational potential. This review summarizes the genetics and pathophysiology of T2DM, candidate-gene approaches, genome-wide association studies, personalized medicine, clinical relevance of pharmacogenetic variants associated with oral hypoglycemic agents, and paths toward personalized diabetology.Keywords: pharmacogenomics, personalized medicine, type 2 diabetes, antidiabetic drugs
format	article
author	Venkatachalapathy P Padhilahouse S Sellappan M Subramanian T Kurian SJ Miraj SS Rao M Raut AA Kanwar RK Singh J Khadanga S Mondithoka S Munisamy M
author_facet	Venkatachalapathy P Padhilahouse S Sellappan M Subramanian T Kurian SJ Miraj SS Rao M Raut AA Kanwar RK Singh J Khadanga S Mondithoka S Munisamy M
author_sort	Venkatachalapathy P
title	Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
title_short	Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
title_full	Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
title_fullStr	Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
title_full_unstemmed	Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
title_sort	pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5053c2f23b274392ac1de3c5ab3daa10
work_keys_str_mv	AT venkatachalapathyp pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT padhilahouses pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT sellappanm pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT subramaniant pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT kuriansj pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT mirajss pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT raom pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT rautaa pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT kanwarrk pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT singhj pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT khadangas pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT mondithokas pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice AT munisamym pharmacogenomicsandpersonalizedmedicineintype2diabetesmellituspotentialimplicationsforclinicalpractice
_version_	1718428981207760896

Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice

Ejemplares similares